Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne F Jones

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Investigational New Drugs|November 9, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinibGrace K Dy, Jeffrey R Infante, S Gail Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerIan E Krop, Muralidhar Beeram, Shanu Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
European Journal of Clinical Pharmacology|August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
The Oncologist|December 15, 2010
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumorsAntoinette R Tan, Afshin Dowlati, Suzanne F Jones, et al.
Investigational New Drugs|September 26, 2015
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatinJhanelle E Gray, Jeffrey R Infante, Les H Brail, et al.
Molecular Cancer Therapeutics|June 9, 2012
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumorsHoward A Burris, Afshin Dowlati, Rebecca A Moss, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Clinical Lung Cancer|September 24, 2005
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II TrialDavid R Spigel, John D Hainsworth, Emily R Burkett, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumoursJeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|November 9, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinibGrace K Dy, Jeffrey R Infante, S Gail Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerIan E Krop, Muralidhar Beeram, Shanu Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
European Journal of Clinical Pharmacology|August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
The Oncologist|December 15, 2010
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumorsAntoinette R Tan, Afshin Dowlati, Suzanne F Jones, et al.
Investigational New Drugs|September 26, 2015
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatinJhanelle E Gray, Jeffrey R Infante, Les H Brail, et al.
Molecular Cancer Therapeutics|June 9, 2012
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumorsHoward A Burris, Afshin Dowlati, Rebecca A Moss, et al.
International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Clinical Lung Cancer|September 24, 2005
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II TrialDavid R Spigel, John D Hainsworth, Emily R Burkett, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumoursJeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Pageof 7